These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 27573624)

  • 1. Priorities for the Priority Review Voucher.
    Ridley DB
    Am J Trop Med Hyg; 2017 Jan; 96(1):14-15. PubMed ID: 27573624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Tropical Disease Priority Review Voucher: A Game-Changer for Tropical Disease Products.
    Berman J; Radhakrishna T
    Am J Trop Med Hyg; 2017 Jan; 96(1):11-13. PubMed ID: 27573627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Commercial Market For Priority Review Vouchers.
    Ridley DB; Régnier SA
    Health Aff (Millwood); 2016 May; 35(5):776-83. PubMed ID: 27140982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of the United States FDA programs as a strategy to advance the development of drug products for neglected tropical diseases.
    Sachs-Barrable K; Conway J; Gershkovich P; Ibrahim F; Wasan KM
    Drug Dev Ind Pharm; 2014 Nov; 40(11):1429-34. PubMed ID: 24512098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preserving an Incentive for Global Health R&D: The Priority Review Voucher Secondary Market.
    Robertson AS
    Am J Law Med; 2016 May; 42(2-3):524-542. PubMed ID: 29086641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is the priority review voucher program stimulating new drug development for tropical diseases?
    Kerr KW; Henry TC; Miller KL
    PLoS Negl Trop Dis; 2018 Aug; 12(8):e0006695. PubMed ID: 30092022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Developing drugs for developing countries.
    Ridley DB; Grabowski HG; Moe JL
    Health Aff (Millwood); 2006; 25(2):313-24. PubMed ID: 16522573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expansion of the Priority Review Voucher Program Under the 21
    Sinha MS; Jain N; Hwang T; Kesselheim AS
    Am J Law Med; 2018 May; 44(2-3):329-341. PubMed ID: 30106661
    [No Abstract]   [Full Text] [Related]  

  • 9. Experience With the Priority Review Voucher Program for Drug Development.
    Kesselheim AS; Maggs LR; Sarpatwari A
    JAMA; 2015 Oct; 314(16):1687-8. PubMed ID: 26414802
    [No Abstract]   [Full Text] [Related]  

  • 10. The economics of priority review vouchers.
    Dimitri N
    Drug Discov Today; 2010 Nov; 15(21-22):887-91. PubMed ID: 20732445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of neglected tropical disease drug and vaccine development pipelines to predict issuance of FDA priority review vouchers over the next decade.
    Stefanakis R; Robertson AS; Ponder EL; Moree M
    PLoS Negl Trop Dis; 2012; 6(10):e1803. PubMed ID: 23145186
    [No Abstract]   [Full Text] [Related]  

  • 12. "Creating hope" and other incentives for drug development for children.
    Connor E; Cure P
    Sci Transl Med; 2011 Jan; 3(66):66cm1. PubMed ID: 21248312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Creative use of the priority review voucher by public and not-for-profit actors delivers the first new FDA-approved treatment for river blindness in 20 years.
    Olliaro PL; Kuesel AC; Halleux CM; Sullivan M; Reeder JC
    PLoS Negl Trop Dis; 2018 Nov; 12(11):e0006837. PubMed ID: 30439940
    [No Abstract]   [Full Text] [Related]  

  • 14. Impact Of The Priority Review Voucher Program On Drug Development For Rare Pediatric Diseases.
    Hwang TJ; Bourgeois FT; Franklin JM; Kesselheim AS
    Health Aff (Millwood); 2019 Feb; 38(2):313-319. PubMed ID: 30715972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug and vaccine development for infectious diseases: the value of priority review vouchers.
    Matheny J; Smith B; Courtney B; Mair M
    Clin Pharmacol Ther; 2009 Jun; 85(6):571-2. PubMed ID: 19451907
    [No Abstract]   [Full Text] [Related]  

  • 16. FDA launches priority vouchers for neglected-disease drugs.
    Waltz E
    Nat Biotechnol; 2008 Dec; 26(12):1315-6. PubMed ID: 19060849
    [No Abstract]   [Full Text] [Related]  

  • 17. Registering medicines for low-income countries: how suitable are the stringent review procedures of the World Health Organisation, the US Food and Drug Administration and the European Medicines Agency?
    Doua JY; Van Geertruyden JP
    Trop Med Int Health; 2014 Jan; 19(1):23-36. PubMed ID: 24134396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The year's new drugs & biologics 2015 - part II:Trends and highlights that marked a complicated year.
    Graul AI; Cruces E; Dulsat C; Tracy M
    Drugs Today (Barc); 2016 Feb; 52(2):131-63. PubMed ID: 27092342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug development for neglected diseases - the trouble with FDA review vouchers.
    Kesselheim AS
    N Engl J Med; 2008 Nov; 359(19):1981-3. PubMed ID: 18987367
    [No Abstract]   [Full Text] [Related]  

  • 20. The Impact of the Priority Review Voucher on Research and Development for Tropical Diseases.
    Aerts C; Barrenho E; Miraldo M; Sicuri E
    Pharmaceut Med; 2022 Jun; 36(3):189-197. PubMed ID: 35588350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.